{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:06:31Z","timestamp":1785391591890,"version":"3.55.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The impact of biologic therapies on body mass index (BMI) in patients with inflammatory bowel disease (IBD) is unclear. This study investigates any associations between BMI, type of IBD, and the type of medications taken among patients with IBD with varying weight categories.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cross sectional study was performed in an IBD tertiary care center. Data was obtained from patients with IBD attending outpatient clinics from January 1st, 2021 until November 1st, 2021. Adult patients, older than 18 years, with a diagnosis of Crohn\u2019s disease (CD) or ulcerative colitis (UC) were recruited. The primary outcome was the association between BMI and medication used in IBD. The secondary outcome was the association between BMI and disease type and location in patients with IBD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included a total of 528 patients of which, 66.5% have CD. Patients with normal weight comprises 55.9% of the participants, while those who are underweight, overweight or obese are 3.4, 28.2, and 12.5%, respectively. None of the underweight patients had UC. Among the normal weight, overweight and obese BMI categories, 34.6% vs. 36.2% vs. 31.8% had UC, respectively. Patients who are on tumor necrosis factor inhibitors (anti-TNF) with an immunomodulator (anti-TNF combination), are more likely to be overweight or obese than patients who are not on anti-TNF combination (OR 2.86, 95% CI 1.739\u20134.711, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). Patients on vedolizumab are twice as likely to be overweight or obese than patients not on vedolizumab (OR 2.23, 95% CI 1.086\u20134.584, <jats:italic>p<\/jats:italic> &amp;lt; 0.05). Patients with ileocolonic CD are more likely to be overweight or obese compared to other subtypes of CD (OR 1.78, 95% CI 1.14\u20132.77, <jats:italic>p<\/jats:italic> = 0.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Many patients with IBD are either obese or overweight. Patients with IBD who are on anti-TNF combination therapy or vedolizumab monotherapy are more likely to be obese and overweight. In addition, patients will ileocolonic CD are more likely to be obese or overweight.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.1045661","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T16:43:40Z","timestamp":1673023420000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of tumor necrosis factor antagonist combination and anti-integrin therapies on body mass index in inflammatory bowel disease: A cross-sectional study"],"prefix":"10.3389","volume":"9","author":[{"given":"Mohammad","family":"Shehab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Hindawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulwahab","family":"Alsayegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Aldallal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israa","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Albaghli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema","family":"Alrashed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Alfadhli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talat","family":"Bessissow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"key":"B1","year":"2022","journal-title":"What is inflammatory bowel disease (IBD)?"},{"key":"B2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/jgh3.12278","article-title":"Malnutrition and quality of life among adult inflammatory bowel disease patients.","volume":"4","author":"Pulley","year":"2020","journal-title":"JGH Open Access J Gastroenterol Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cgh.2021.06.049","article-title":"Obesity is associated with increased risk of crohn\u2019s disease, but not ulcerative colitis: a pooled analysis of five prospective cohort studies.","volume":"20","author":"Chan","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"7868","DOI":"10.3748\/wjg.v22.i35.7868","article-title":"Interaction of obesity and inflammatory bowel disease.","volume":"22","author":"Harper","year":"2016","journal-title":"World J Gastroenterol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1046\/j.1467-789x.2001.00040.x","article-title":"Quality of life and obesity.","volume":"2","author":"Kolotkin","year":"2001","journal-title":"Obes Rev Off J Int Assoc Study Obes."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6134362","article-title":"Epidemiology, predisposing factors, biomarkers, and prevention mechanism of obesity: a systematic review.","volume":"2020","author":"Endalifer","year":"2020","journal-title":"J Obes."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-10692-1","article-title":"Prevalence of overweight and obesity, and associations with socio-demographic factors in Kuwait.","volume":"21","author":"Oguoma","year":"2021","journal-title":"BMC Public Health."},{"key":"B8","year":"2022","journal-title":"A different scale: global action to address obesity."},{"key":"B9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrgastro.2016.181","article-title":"Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes.","volume":"14","author":"Singh","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1161\/01.CIR.0000130640.77501.79","article-title":"Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences.","volume":"109","author":"Greenfield","year":"2004","journal-title":"Circulation."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1007\/s10620-020-06442-9","article-title":"Assessment of body weight changes in patients with inflammatory bowel diseases initiating biologic therapy: a prospective cohort study.","volume":"65","author":"Borren","year":"2020","journal-title":"Dig Dis Sci."},{"key":"B12","year":"2021","journal-title":"Obesity and overweight."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg."},{"key":"B14","year":"2015","journal-title":"International Statistical Classification of Diseases and Related Health Problems 2016, 10th revision"},{"key":"B15","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The montreal classification of inflammatory bowel disease: controversies, consensus, and implications.","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00481","article-title":"Impact of TNF-a inhibitors on body weight and BMI: a systematic review and meta-analysis.","volume":"11","author":"Patsalos","year":"2020","journal-title":"Front Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaad.2019.07.103","article-title":"Change in body weight and body mass index in psoriasis patients receiving biologics: a systematic review and network meta-analysis.","volume":"82","author":"Wu","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.2337\/db13-0138","article-title":"Direct effects of TNF-\u03b1 on local fuel metabolism and cytokine levels in the placebo-controlled, bilaterally infused human leg: increased insulin sensitivity, increased net protein breakdown, and increased IL-6 release.","volume":"62","author":"Bach","year":"2013","journal-title":"Diabetes."},{"key":"B19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.20524\/aog.2022.0699","article-title":"Effect of obesity on vedolizumab response in inflammatory bowel disease.","volume":"35","author":"Levine","year":"2022","journal-title":"Ann Gastroenterol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1054\/clnu.2001.0503","article-title":"Crohn\u2019s disease clinical course and severity in obese patients.","volume":"21","author":"Braga","year":"2002","journal-title":"Clin Nutr."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1136\/bmj.308.6939.1259","article-title":"Juvenile onset inflammatory bowel disease: height and body mass index in adult life.","volume":"308","author":"Ferguson","year":"1994","journal-title":"BMJ."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1097\/MIB.0000000000000832","article-title":"Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease.","volume":"22","author":"Bessissow","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1097\/MIB.0b013e31829936a4","article-title":"The increasing weight of Crohn\u2019s disease subjects in clinical trials: a hypothesis-generatings time-trend analysis.","volume":"19","author":"Moran","year":"2013","journal-title":"Inflamm Bowel Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/MIB.0000000000000283","article-title":"Measures of obesity and risk of Crohn\u2019s disease and ulcerative colitis.","volume":"21","author":"Khalili","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9010035","article-title":"Impact of body mass index on the development of inflammatory bowel disease: a systematic review and dose-response analysis of 15.6 million participants.","volume":"9","author":"Bhagavathula","year":"2021","journal-title":"Healthc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cgh.2019.11.009","article-title":"Management of inflammatory bowel diseases in special populations: obese, old, or obstetric.","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1177\/2050640620954556","article-title":"Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: results from the Swiss inflammatory bowel disease cohort.","volume":"8","author":"Greuter","year":"2020","journal-title":"United Eur Gastroenterol J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1097\/MIB.0000000000000560","article-title":"Impact of obesity on the management and clinical course of patients with inflammatory bowel disease.","volume":"21","author":"Seminerio","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1007\/s10620-015-3629-5","article-title":"Obesity in inflammatory bowel disease: a marker of less severe disease.","volume":"60","author":"Flores","year":"2015","journal-title":"Dig Dis Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1097\/MIB.0b013e31829cf401","article-title":"Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease.","volume":"19","author":"Harper","year":"2013","journal-title":"Inflamm Bowel Dis."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis.","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One."},{"key":"B32","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.cgh.2017.11.050","article-title":"Association of vedolizumab level, anti-drug antibodies, and \u03b14\u03b27 occupancy with response in patients with inflammatory bowel diseases.","volume":"16","author":"Ungar","year":"2018","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103142","article-title":"Vedolizumab serum trough concentrations and response to dose escalation in inflammatory bowel disease.","volume":"9","author":"Vaughn","year":"2020","journal-title":"J Clin Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/ibd\/izy272","article-title":"Vedolizumab drug level correlation with clinical remission, biomarker normalization, and mucosal healing in inflammatory bowel disease.","volume":"25","author":"Al-Bawardy","year":"2019","journal-title":"Inflamm Bowel Dis."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1045661\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T16:43:42Z","timestamp":1673023422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1045661\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,6]]},"references-count":34,"alternative-id":["10.3389\/fmed.2022.1045661"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1045661","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,6]]},"article-number":"1045661"}}